Cancer patients who are undergoing targeted therapy
can look forward to a new blood test that could tell their doctors
whether the treatment is working, within one day after the start of
the treatment. This will significantly speed up the evaluation
process and enable doctors to make adjustments to the treatment
plan, if necessary, to improve patients’ chances of
recovery.